¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ 2020 the 30th KGOG Symposium and Workshop : 2020-08-15

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ 2020 the 30th KGOG Symposium and Workshop : 2020-08-15
±³À°ÀÏÀÚ : 2020-08-15
±³À°Àå¼Ò : ½¦¶óÅæ¼­¿ï°­³²È£ÅÚ ±×·£µåº¼·ë  
±³À°ÁÖÁ¦ : 2020 the 30th KGOG Symposium and Workshop      
ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸  
´ã´çÀÚ : ±èÀμ÷
¿¬¶ôó : 02-512-540  
À̸ÞÀÏ : koreagyonco@hanmail.net      
±³À°Á¾·ù : »êºÎÀΰú      
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 30,000¿ø      
ºñ°í       
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 08:10~09:00 Disease site subcommittee workshop-Cervix-vulvar TSC  ±è´ë¿¬, ±è¹®È«(¼­¿ï¾Æ»êº´¿ø, ¿øÀڷº´¿ø) 
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 09:00~09:30 Rare tumor subcommittee, DDT subcommittee _ overview  Á¤ÇöÈÆ, ±è±âµ¿(¼­¿ï´ëº´¿ø, ºÐ´ç¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 09:30~10:10 Future treatment strategy based on VEGF inhibitor in Frontline Ovarian Cancer: for the new normal through cancer immunotherapy  ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 10:30~11:10 Virtual-The recent status and experience of the international and USA clinical trial collaboration  Robert Mannel(GOG, USA) 
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 11:10~11:30 Virtual-Update of establishing the clinical trial network in East-asian area based on the experience between KGOG and JGOG  Takayuki Enomoto(JGOG, Japan) 
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 11:30~11:50 Virtual-Overview of clinical trial of cervical cancer in CGCS (China)  Xiaohua Wu(CGCS, China) 
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 11:50~12:10 Virtual-Experience of clinical trial of GYN Cancer in TGOG  Kung-Liahng Wang(TGOG, Taiwan) 
Åä·Ð 08¿ù 15ÀÏ ±×·£µåº¼·ë 12:10~12:20 Discussion  () 
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 12:20~12:50 Management of chemotherapy induced neutropenia and the role of long-acting G-CSF  À¯ÇåÁ¾(Ãæ³²´ëº´¿ø) 
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 13:30~13:50 Current trends in immuno-oncology on endometrial cancer treatment  Kevin Chueh(MSD, A-P) 
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 14:00~14:50 Disease site subcommittee workshop-Uterine corpus TSC  Àå¼®ÁØ, À̱¤¹ü(¾ÆÁִ뺴¿ø, ±æº´¿ø) 
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 14:50~15:10 Second-line maintenance of ovarian cancer  À̼ºÁ¾(¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 15:10~15:30 First-line maintenance therapy with newly diagnosed advanced ovarian cancer  ¾î°æÁø(¿ëÀμ¼ºê¶õ½ºº´¿ø) 
Åä·Ð 08¿ù 15ÀÏ ±×·£µåº¼·ë 15:30~15:40 Discussion  () 
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 16:00~16:50 Disease site subcommittee worhshop-ovary tsc  °­¼®¹ü, ÀÌÁ¤¿ø(±¹¸³¾Ï¼¾ÅÍ, »ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 16:50~17:40 Niraparib in patients with newly diagnosed advanced ovarian cancer: PRIMA  ±è´ë¿¬(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 08¿ù 15ÀÏ ±×·£µåº¼·ë 17:40~18:00 Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer: NOVAPARPi monotherapy for late-line treatment of ovarian cancer  ±è»ó¿î(¼¼ºê¶õ½ºº´¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ 2020 the 30th KGOG Symposium and Workshop : 2020-08-15""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѼÒÈ­±â±â´É¼ºÁúȯ¹×¿îµ¿ÇÐȸ APNM 2020 : 2020-08-15
´ÙÀ½±Û ´ëÇÑ°£ÇÐȸ (¿Â¶óÀÎ)The Liver Week 2020 Virtual Confernence Day 2 : 2020-08-14
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20910 ¼­¿ï 2024³â Á¦14ȸ °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»ºÐºñ³»°ú ¿¬¼ö°­Á : 2024-07-07 0 11 2024-05-28
20909 °æ±â ¾ÆÁÖ´ëÇб³º´¿ø Á¤Çü¿Ü°ú 30Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2024-07-07 0 18 2024-05-28
20908 ¼­¿ï Á¦19Â÷ ´ëÇѸðÀ¯¼öÀ¯ÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-07-07 0 14 2024-05-28
20907 °æ±â Á¦2Â÷ ´ëÇѽŰæ¹æ»ç¼±¼ö¼úÇÐȸ Á¤±âÇмú´ëȸ : 2024-07-06 0 11 2024-05-28
20906 °æ±â Á¦ 5ȸ ¿À»ê½ÃÀÇ»çȸ Çмú´ëȸ : 2024-07-06 0 12 2024-05-28
20905 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø Á¦3ȸ ¾Æ»êµÎ°æºÎ Æ÷·³ : 2024-07-06 0 15 2024-05-28
20904 ¼­¿ï 2024³â Á¦2ȸ °¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿ø ¼øȯ±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-06 0 13 2024-05-28
20903 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day3) : 2024-07-06 0 12 2024-05-28
20902 ¼­¿ï ´ëÇѽŰæÁýÁßÄ¡·áÇÐȸ 2024³â ÇÏ°è NeurocrItical Care Essence (NICE) ¾ÆÄ«µ¥¹Ì : 2024-07-06 0 9 2024-05-28
20901 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø Á¦10ȸ ºÎ½Å¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-06 0 3 2024-05-28
20900 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day2) : 2024-07-05 0 5 2024-05-28
20899 ¼­¿ï ÀÓ»ó¼ú±â±³À°¿¬±¸È¸ Á¦16ȸ ÀÓ»ó¼ú±â ¿¬¼ö°­Á : 2024-07-04 0 11 2024-05-28
20898 °æ±â ¿ëÀμ¼ºê¶õ½ºº´¿ø µðÁöÅÐÀÇ·á½ÉÆ÷Áö¾ö -¹Ì·¡ ÀǷḦ À§ÇÑ ±³·ù¿Í Çù·Â : 2024-07-04 0 9 2024-05-28
20897 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day1) : 2024-07-04 0 9 2024-05-28
20896 ¼­¿ï ´ëÇÑ»êºÎÀΰúÇÐȸ ¼­ºÎÁöȸ Á¤±â Áý´ãȸ(Àڱ󻸷Áõ½ÄÁõ) : 2024-07-02 0 8 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷